Literature DB >> 9728853

Oral antihistamines reduce the side effects from rapid vancomycin infusion.

C L Renz1, J D Thurn, H A Finn, J P Lynch, J Moss.   

Abstract

UNLABELLED: Rapid infusion of vancomycin causes histamine-mediated side effects, hypotension, and rash, known as "red man syndrome." In this prospective, randomized, double-blind, placebo-controlled study, we examined the ability of oral antihistamines to attenuate three clinical end points: rash, hypotension, and vancomycin discontinuation, and we compared these findings with those of a similar study using IV antihistamines. Patients (ASA physical status I-III) who required vancomycin prophylaxis for elective arthroplasty received either oral antihistamines (diphenhydramine < or = 1 mg/kg and cimetidine < or = 4 mg/kg, n = 20) or placebo (n = 10) 1 h before rapid vancomycin infusion (1 g over 10 min). The vancomycin infusion was discontinued if the mean arterial blood pressure decreased by > or = 20% or if itching was intolerable for the patient. Clinically significant hypotension developed in no treated patients, compared with five (50%) patients in the placebo group (P = 0.001). Rapid infusion was stopped for one treated patient (5%) and for five (50%) patients in the placebo group (P = 0.004). Incidence (P = 0.011) and severity of rash (P = 0.015) were also reduced in treated patients. Peak histamine levels were increased but were similar for patients in both groups (mean +/- SD, 1.9+/-2.5 vs 1.6+/-2.4 ng/mL; P = 0.75). Oral antihistamines were as effective as IV antihistamines. In conclusion, oral H1 and H2 antihistamine pretreatment is a practical, safe, and inexpensive option to attenuate histamine-mediated side effects associated with rapid vancomycin infusion. IMPLICATIONS: Clinicians often must administer vancomycin faster than the 1-h recommended time, which can cause "red man syndrome" (rash, itching, hypotension). Our randomized, double-blind, placebo-controlled study showed that oral H1 and H2 antihistamine pretreatment significantly reduced the histamine-related side effects of rapid vancomycin infusion.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9728853     DOI: 10.1097/00000539-199809000-00036

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  6 in total

1.  Vancomycin-induced red man syndrome in pediatric oncology: still an issue?

Authors:  Tiene Bauters; Barbara Claus; Petra Schelstraete; Hugo Robays; Yves Benoit; Catharina Dhooge
Journal:  Int J Clin Pharm       Date:  2011-12-13

2.  Hypersensitivity reactions to non beta-lactam antimicrobial agents, a statement of the WAO special committee on drug allergy.

Authors:  Mario Sánchez-Borges; Bernard Thong; Miguel Blanca; Luis Felipe Chiaverini Ensina; Sandra González-Díaz; Paul A Greenberger; Edgardo Jares; Young-Koo Jee; Luciana Kase-Tanno; David Khan; Jung-Won Park; Werner Pichler; Antonino Romano; Maria José Torres Jaén
Journal:  World Allergy Organ J       Date:  2013-10-31       Impact factor: 4.084

3.  Systemic Toxicity of Intraperitoneal Vancomycin.

Authors:  Teerath Kumar; Iris Teo; Brendan B McCormick
Journal:  Case Rep Nephrol       Date:  2016-10-20

4.  Vancomycin induced cardiac arrest: a case report.

Authors:  Sharad Khakurel; Sangam Rawal
Journal:  J Med Case Rep       Date:  2021-02-16

5.  An elderly woman with 'Red Man Syndrome' in association with oral vancomycin therapy: a case report.

Authors:  Phillippa Bailey; Henry Gray
Journal:  Cases J       Date:  2008-08-18

6.  Pruritus: a useful sign for predicting the haemodynamic changes that occur following administration of vancomycin.

Authors:  Massimo Bertolissi; Flavio Bassi; Roberta Cecotti; Carlo Capelli; Francesco Giordano
Journal:  Crit Care       Date:  2002-04-25       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.